US 2023/0416357 A1 · ANTIBODIES AGAINST INTERLEUKIN-22

Abstract

The present invention relates to antibodies binding to IL22 and inhibiting its interaction with one or more of its natural ligands Specific examples of such antibodies are provided. The therapeutic uses of the antibodies and methods of generating such C are also provided.

Claims33

Dependent claims

An isolated antibody that binds to interleukin 22 (IL22) and inhibits or attenuates IL22 binding to IL22 receptor 1 (IL22R1).

Dependencies are inferred from the claim text.

Facts

Application

18/253,240Filed 6 Dec 2021

Priority

EP 20212127.37 Dec 2020

Published

28 Dec 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

C07K 16/244
Against cytokines, lymphokines or interferons: interleukins [IL]
C07K 2317/24
Characterized by taxonomic origin: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/33
Characterized by aspects of specificity or valency: crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/34
Characterized by aspects of specificity or valency: identification of a linear epitope shorter than 20 amino acid residues or of a conformational…

Abstract

Claims33

Dependent claims

An isolated antibody that binds to interleukin 22 (IL22) and inhibits or attenuates IL22 binding to IL22 receptor 1 (IL22R1).

Dependencies are inferred from the claim text.

Antibodies against interleukin-22

Life of this patent

Abstract

Claims33

Antibodies against interleukin-22

Life of this patent

Abstract

Claims33